The s100β Levels in Patients With Mild Brain Injury.

Launched by SUMEI LU · Nov 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new test that measures a protein called S100β in patients with mild brain injuries, such as concussions. The goal is to see if this test can help doctors decide which patients really need a CT scan to check for serious brain injuries. Currently, most people with mild brain injuries don’t show any problems on a CT scan, so the trial aims to find a better way to identify those who are at low risk and can avoid unnecessary tests, which can save both time and money.

To participate in the trial, individuals must be at least 18 years old and either healthy or have a suspected brain injury with a mild score on the Glasgow Coma Scale, which checks how awake and responsive a person is. Participants will be asked to provide samples for the S100β test, and their results will help establish standard levels for the Chinese population. This study is important as it could lead to improved care for patients with mild brain injuries in China, ensuring that only those who need further examination receive it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Study on healthy people: Apparently healthy people \>18 years old who came to our hospital for physical examination.
• • 2. Study of emergency trauma patients: 1) Emergency trauma patients at least 18 years old with suspected brain injury; 2) Glasgow Coma Score 13-15 (patients with mild traumatic brain injury); 3) Closed head trauma; 4) Clinical judgment of patients requiring craniocerebral CT examination.
• Exclusion Criteria:
• • 1. Healthy population study: stroke history, trauma, surgery, mental illness, senile dementia, cognitive impairment, and tumor patients within 3 months.
• • 2. Study of emergency trauma patients: 1) neurological or psychiatric history, 2) intellectual disabilities, 3) alcohol or drug addiction (trauma after drinking was eligible for inclusion, but alcohol consumption was recorded), 4) brain tumor patients, 5) time of trauma was not available, and 6) patients whose clinical conditions were deemed unsuitable for participation in the trial.